Mydfrin

Phase 2Small molecule

MMontefiore Medical Center

Mydfrin is one of 13 small molecule programs targeting Mitral regurgitation. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Mitral RegurgitationRecruiting

Mitral RegurgitationPhase 2

Recruiting

Competition

Competitive Landscape

17 competitors in Mitral Regurgitation

#DrugCompanyPhaseTrials

Periactin

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Phase 2

1 2

Aldactone

Pfizer

Preclinical

2 3

Plavix

Sanofi

Preclinical

1 4

Bayer Aspirin

Bayer

Preclinical

1 5

Jardiance

Boehringer Ingelheim

Preclinical

1 6

Demadex

SSarfez Pharmaceuticals, Inc.

Preclinical

1 7

Potassium Iodide

MMeda Pharmaceuticals

Preclinical

1 8

Mydfrin

MMontefiore Medical Center

Phase 2

1 9

Medication

NNYU Langone Health

Preclinical

1 10

Drug

EElro Pharma

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Mitral regurgitation1 trial

Use of Phenylephrine for Assessment of Mitral Regurgitation Severity

Recruiting·MMontefiore Medical Center·Phase 1/2·NCT04500899·35 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Mydfrin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Mydfrin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Mydfrin. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Montefiore Medical Center company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: MMontefiore Medical Center

Mydfrin

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Mitral regurgitation1 trial

References

Drug Info

Quick Facts

Related News